

FOR IMMEDIATE RELEASE

NEWS RELEASE

**THOMSON MEDICAL GROUP TO CREATE ASIA'S LEADING
ASSISTED REPRODUCTION PLATFORM IN PARTNERSHIP WITH
WORLD LEADER IVI-RMA GLOBAL**

Singapore, 27 July 2018 – Thomson Medical Group (TMG) today signed an agreement with IVI-RMA Global (IVI-RMA) – the largest medical group in the world specialising in assisted reproductive technologies (ART) – that will see the two groups form an exclusive joint venture to become the dominant platform in Asia¹. To be headquartered out of Singapore, the joint venture seeks to deliver industry-leading clinical services, training and education, and research in the region with the fastest growing demand for assisted reproduction services.

2. Global demand for assisted reproduction (mainly through IVF procedures) has been on an upward trend and is projected to grow significantly, particularly in Asia. The total value of the global ART industry is estimated at US\$22 billion in 2016 and is expected to grow to US\$38 billion by 2025². Within Asia, the overall number of IVF cycles performed in the region stood at 329,300 in 2013 and is projected to grow to more than double to 779,400 by 2020. The total value of Asia's IVF market is expected to reach US\$4.2 billion by 2020³.

3. The partnership between TMG and IVI-RMA Global aims to bring the best and latest technology, knowledge and expertise to address the growing demand for assisted reproduction in Asia, especially in markets such as China, Indonesia and Vietnam.

4. IVI-RMA is currently the largest assisted reproduction group in the world. It operates more than 70 clinics spread mainly across Europe and the Americas⁴. The group is made up of a multidisciplinary team comprising more than 2,000 medical professionals specialising in Gynaecology, Obstetrics, Genetics, Biology, Andrology, Surgery and Maternal-Foetal Medicine. IVI-RMA is led by world-renowned and highly-

¹ Asia, Australia, New Zealand, excluding India and the Middle East.

² [Statistics by Transparency Market Research](#)

³ Studies by Allied Market Research

⁴ Spain, Argentina, Brazil, Chile, India, Italy, Mexico, Oman, Panama, Portugal, United Arab Emirates, United Kingdom and United States of America.

respected assisted reproduction specialists Dr Richard Scott, Dr Antonio Pellicer and Dr José Remohí (*refer to Annex A*)

5. TMG is the market leader for private ART in South East Asia. The partnership with IVI-RMA will enable the group to expand into the rest of Asia and become an integrated service, training and education, and research platform. This will be a first for private ART in Asia. Singapore will host the third research centre for IVI-RMA in the world, after Valencia (for Europe) and New Jersey (for the Americas). The Singapore centre will serve the whole Asian region.

6. Mr Ng Ser Miang, Chairman, Thomson Medical Group said: “As a leading women and children’s healthcare services provider and one of the pioneers of IVF in Singapore, Thomson Medical has been helping families realise their dreams of parenthood for close to 40 years. As we work towards our vision of transforming into Asia’s preferred integrated health system, we are very excited at the prospect of working with IVI-RMA Global to build the best possible platform in the field of ART. I want to congratulate the TMG team for this milestone agreement. It is no mean feat to reach agreement with such an esteemed and valuable partner as IVI-RMA Global. This is testament to TMG’s own position as the regional leader in ART and we now look forward to becoming the dominant platform in Asia.”

ABOUT THOMSON MEDICAL GROUP LIMITED

Listed on the Mainboard of the Singapore Exchange, Thomson Medical Group Limited is one of Asia's largest healthcare players.

The Group's healthcare business includes **Thomson Medical** and **TMC Life Sciences Berhad**. Established in 1979, **Thomson Medical** is Singapore's largest private provider of healthcare services for women and children. It owns and operates the iconic Thomson Medical Centre and a network of specialist medical clinics and facilities in Singapore. **TMC Life Sciences Berhad** is a multi-disciplinary healthcare company listed on Bursa Malaysia. It operates **Thomson Hospital Kota Damansara**, a tertiary hospital located in Kota Damansara, and the award-winning TMC Fertility Centre which is the industry leader in assisted reproduction in Malaysia. TMC Life Sciences also owns Thomson Iskandar Medical Hub, which is adjacent to Vantage Bay Healthcare City in Iskandar Malaysia. Sited on freehold waterfront land in Johor Bahru's City Centre, **Vantage Bay Healthcare City** is conceived as a first-of-its-kind integrated medical, education and wellness hub.

For more information, please visit: www.thomsonmedicalgroup.com

For financial enquiries, kindly contact:

Mr Tan Zing Yuen
Chief Financial Officer, Thomson Medical Group Limited
Tel: +65 6311 9888
Mobile: +65 9838 9044
Email: zingyuen@thomsonmedical.com

For media enquiries, kindly contact:

Mr Warren Wu
Corporate Communications, Thomson Medical Group Limited
Tel: +65 6511 3147
Mobile: +65 9170 0175
Email: warrenwu@thomsonmedical.com

Dr Antonio Pellicer



He studied Medicine at the Faculty of Valencia, specialising in Obstetrics and Gynaecology at the Valencia Clinical Hospital, with the subspeciality of Reproductive Medicine at Yale University (USA) and the University of Mainz (Germany). He became Professor of Obstetrics and Gynaecology at the University of Valencia in 1999 and was Dean of the Faculty of Medicine and Dentistry from 2006 to 2012. He has been Head of the Obstetrics and Gynaecology Department at the La Fe University Hospital since 2009. Professor Pellicer has been a member of the Executive Board of ESHRE (European Society of Human Reproduction and Embryology), and the International Federation of Fertility Societies. He was President of the Spanish Fertility Society (SEF) from 1994 to 1996 and is currently a member of the National Commission of Human Assisted Reproduction. He has published more than 800 articles in prestigious national and international magazines, written more than 300 chapters of books and he has given more than 475 lectures at conferences all over the world. He is also co-editor of the Fertility & Sterility Magazine and member of the editorial boards of several scientific societies. Professor Pellicer has received many different awards for his contribution to the field of reproductive health, including some very prestigious ones. The American Society for Reproductive Medicine has awarded him the Annual Meeting Prize Paper seven times. He won the XXV Society for Gynaecological Investigation President's Award in 2002, the Premio Rey Jaime I award in the category of Clinical Medicine which was presented by the Fundación Premios Rey Jaime I in Valencia in 2004, the Medalla de Oro award from the Ilustre Colegio Oficial de Médicos de Valencia in 2006, the Fundación Lilly 2008 Award for Biomedical Research, presented by Fundación Lilly in Madrid in 2008, and he received an honorary doctorate from the Polytechnic University of Valencia in 2011. In addition to this he won the Jacques Salat-Baroux Prize which was presented to him by the Académie Nationale de Médecine de France in 2014 and the award that recognises IVI as an Honorary Ambassador of Marca España (the Spanish brand) in Science and Innovation in 2015.

Dr José Remohí



He studied Medicine at the University of Valencia, specialising in Obstetrics and Gynaecology at the Clinical Hospital in the same city and within this further specialising in Reproductive Obstetric Endocrinology at the University of California, Irvine (USA). He has also been a maternologist since 1984 and a sexologist since 1986. He is currently Professor of Obstetrics and Gynaecology at the University of Valencia, as well as Director of the Master's in Advanced Gynaecological Endoscopic Surgery at the University of Valencia and Director of the Instituto Universitario IVI. Professor Remohí is a member of the Sociedad Española de Fertilidad (Spanish Fertility Society), the European Society of Human Reproduction and Embryology (ESHRE), the American Society for Reproductive Medicine (ASRM) and of the Advisory Board of Universidad Europea, among others. He is the author of 22 books on reproductive medicine, two of which have been translated into English, one into Portuguese and one into Chinese. He has published more than 650 studies in national and international journals, around 385 chapters in books relating to human reproduction and he has given more than 600 lectures at conferences all over the world. He is ranked third at present in the listings of the top researchers in Spain in the category of Obstetrics and Gynaecology, based on the h-index, with a value of 55. Furthermore, he is a reviewer for prestigious journals such as Human Reproduction, the Journal of Assisted Reproduction and Genetics and Cuadernos de Medicina Reproductiva (the Journal of Reproductive Medicine). He is also a member of the editorial board of the latter, as well as for the journal of the Asociación Colombiana de Fertilidad (Colombian Fertility Association), the Revista Ciencia Ginecológica (Journal of Gynaecological Science) and the Revista de Obstetricia y Ginecología de Postgrado (Journal of Postgraduate Obstetrics and Gynaecology). Professor Remohí has won many prestigious awards for his contribution to the field of reproductive health. These include the Ares-Serono Foundation prize in 1997, awards from the ASRM in 1995, 1999, 2001, 2008 and 2014 and research awards from the Spanish Fertility Society in 1987, 1996, 1998, 2000, 2002 and 2004, to name but a few. Furthermore, he has received various social awards, such as the Protagonistas Onda Cero prize for the best scientific career in 2002, the Premio Investigación Economía 3 award in 2004, a Gold Medal of the City of Valencia for IVI in recognition of his pioneering work in research and education in 2006, the Empresa Revelación del Año (Newcomer of the Year) award from Expansión magazine in 2009, the Tendencias magazine prize in 2015 and the award that recognises IVI as an Honorary Ambassador of Marca España in Science and Innovation in 2015, among others.

Dr Richard Scott



- Chief Executive Officer, IVI-RMA Global
- Founding Partner, Reproductive Medicine Associates of New Jersey
- Professor and Fellowship Director, Division of Reproductive Endocrinology, Sidney Kimmel Medical College of Thomas Jefferson University
- Professor, Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School
- Embryology, preimplantation genetic screening (PGD), and non-invasive screening of embryonic reproductive competence.
- Over 500 published scientific papers and abstracts
- SART Prize Paper, The American Society for Reproductive Medicine, 2009, 2010
- US News & World Report Top Doctors 2016
- New Jersey Monthly Magazine Top Docs Award 2016
- Castle Connolly Top Doctors: New York Metro Area 2016